SCHEMBL10123462

SCHEMBL10123462

CC(F)(F)C(C)(NC(=O)Nc1cccc(OC(F)(F)F)c1)C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ EPHX2 P34913 1/20 0.53
▸ PDK1 Q15118 1/20 0.51
▸ PDK2 Q15119 1/20 0.51
▸ PDK3 Q15120 1/20 0.51
▸ PDK4 Q16654 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MAPT P10636 3/20 0.50
▸ GAA P10253 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ P2RX1 P51575 1/20 0.49
▸ TP53 P04637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419483 0.95 HTT (0.60) HTTMEN1KMT2AEPHX2PDK1
SCHEMBL10123473 0.88 PDK1 (0.62) HTTMEN1KMT2APDK1PDK2
SCHEMBL10123506 0.84 EPHX2 (0.67) KMT2AEPHX2NPC1RAB9AMAPT
SCHEMBL418319 0.83 PDK1 (0.65) HTTMEN1KMT2APDK1PDK2
SCHEMBL13993361 0.83 RAB9A (0.61) HTTMEN1KMT2APDK1PDK2
SCHEMBL10123510 0.81 KMT2A (0.59) HTTMEN1KMT2ANPC1RAB9A
SCHEMBL10123543 0.81 MEN1 (0.59) HTTMEN1KMT2ANPC1RAB9A
SCHEMBL13993503 0.80 KMT2A (0.62) HTTMEN1KMT2AEPHX2RAB9A
SCHEMBL12061944 0.79 LMNA (0.73) HTTEPHX2PDK1PDK2PDK3
SCHEMBL10123470 0.79 MAPT (0.64) HTTMEN1KMT2AEPHX2PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012060820-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2012-05-10 — — WO disclosed
Send feedback